Home  Contact Us
  Follow Us On:
 
Search:
Advertising Advertising Free Newsletter Free E-Newsletter
NEWS

UK first to approve Omicron COVID shot with Moderna no
Published on: 2022-08-17
Share to
User Rating: / 0
PoorBest 

Britain, the first country to approve a coronavirus vaccine in late 2020, has now also given the first green light to a variant-adapted shot that targets both the original and Omicron version of the virus.
 

The UK medicines regulator (MHRA) gave the so-called bivalent vaccine made by US drug company Moderna conditional approval as a booster for adults on Monday.
 

Later on Monday, the UK's Joint Committee on Vaccination and Immunisation (JCVI) backed the use of the variant-adapted shot in the country's booster campaign starting in September.
 

The MHRA's Moderna decision was based on clinical trial data that showed the booster triggered "a strong immune response" against both Omicron (BA.1) and the original virus, it said.
 

Moderna in June said trial data showed that when given as a fourth dose, the variant-adapted shot raised virus-neutralizing antibodies by eight-fold against Omicron.
 

The MHRA also cited an exploratory analysis in which the shot was found to generate a "good immune response" against the currently dominant Omicron offshoots BA.4 and BA.5.
 

According to Moderna, trial data showed its variant-adapted booster generated virus-neutralizing antibody levels against the subvariants that were 1.69 times higher than those given the original booster.
 

英国率先批准专门针对奥密克戎的新冠疫苗

当地时间8月15日,英国成为世界上首个批准针对新冠病毒变异株奥密克戎疫苗的国家。
 

据路透社15日报道,二价原版疫苗和奥密克戎BA.1疫苗当天获得了英国政府的绿灯。英国药品和保健品监管机构(MHRA)批准了美国莫德纳(Moderna)公司生产的二价疫苗供成人接种。随后,英国疫苗接种和免疫联合委员会(JCVl)又批准了从9月开始使用该公司生产的该款疫苗。

Comments (0)Add Comment

Write comment

security code
Write the displayed characters


busy
    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2022 BusinessTianjin.com. All rights reserved.